Notifications Bell

European Union vs AstraZeneca

European Union vs AstraZeneca

The European Union is suing AstraZeneca over shortfalls in the deliveries of its COVID-19 vaccine

Earlier today, the European Union confirmed that it’s taking legal action against the British - Swiss pharma company, AstraZeneca.

The EU’s action came after, in March, the European Commission President Ursula von der Leyen expressed her disappointment with the company. According to her statement, “AstraZeneca has unfortunately under-produced and under-delivered. And this painfully, of course, reduced the speed of the vaccination campaign.” So far this year, the EU and AstraZeneca have been at odds multiple times. The drug company announced that it wouldn’t deliver as many vaccines as the bloc was counting on, both during the first and the second quarter.

In the first three months of the year, the bloc expected 120 million doses but received only about 30 million. For Q2, it was hoping 70 million doses, down from 180 million originally anticipated.

According to AstraZeneca CEO Pascal Soriot, the low yields at the EU production plants were causing the delays. It has caused a postponement of vaccine’s rollouts in 27 European countries.

Later this week, all eyes will be again on the pharma company due to report quarterly figures on Friday.

Read more about the upcoming earnings reports here!


This information prepared by is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.

This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.

Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of